Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 25, 2013

Myriad to Perform BRCA Testing in CDx Deal with Tesaro

  • Less than two weeks after the Supreme Court struck down its gene patents, Myriad Genetics has moved on, inking an agreement with cancer-focused biopharmaceutical company Tesaro to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in two separate Phase III clinical studies evaluating the PARP inhibitor niraparib. 

    Tesaro's two Phase III clinical studies on niraparib include one in platinum-sensitive, high-grade serous ovarian cancer patients, which is planned to begin enrolling patients in mid-2013; the other, involving metastatic breast cancer patients who have germline BRCA mutations, is slated to begin during second half of 2013. Myriad's BRACAnalysis® test, which can be used to detect BRCA1 or BRCA2 mutations, will be used as a companion diagnostic to identify patients for these clinical trials.

    "We believe this agreement reinforces BRACAnalysis as the gold standard companion diagnostic test for this exciting new class of therapeutics," said Peter Meldrum, president and CEO of Myriad Genetics. "This collaboration is yet another example of Myriad's strong commitment to becoming a leader in the field of companion diagnostics."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »